AI assistant
Sending…
Gain Therapeutics, Inc. — Director's Dealing 2021
Mar 18, 2021
34440_dirs_2021-03-17_48a068b1-cfc3-4804-b763-7ccedbb7e4d4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Gain Therapeutics, Inc. (GANX)
CIK: 0001819411
Period of Report: 2021-03-17
Reporting Person: Islam Khalid (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 880784 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $3.37 | 2031-01-22 | Common Stock (25000) | Direct |
Footnotes
F1: The Reporting Person is the ultimate shareholder of 1 MM & 1 PP AG, which is the direct beneficial owner of the securities.
F2: The option will be fully vested and exercisable on January 22, 2022.
More from Gain Therapeutics, Inc.
Regulatory Filings
2026
May 26
Proxy Solicitation & Information Statement
2026
Apr 28
Director's Dealing
2026
Mar 27
Director's Dealing
2026
Mar 27
Regulatory Filings
2026
Mar 18
Investor Presentation
2026
Feb 3
Regulatory Filings
2025
Dec 18
Regulatory Filings
2025
Dec 3
Capital/Financing Update
2025
Nov 28
Capital/Financing Update
2025
Nov 28